Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!! -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (67)	9/21/1999 11:42:00 PM
From: Spiney	Respond to of 94

I believe Dr. Curry is in Italy right now at a conference...dealing with the glutamate receptor [ CNS ] thing <?> All the big pharmaceuticals are represented...I'm sure they are talking. Animal studies should be completed in the next few weeks. Loads of resistance at .90 I think it will take some positive news on the animal studies, or a deal with a large pharma to move through 1.00 That could happen at anytime now! spiney

To: David Culver who wrote (67)	10/1/1999 1:36:00 AM
From: Spiney	Respond to of 94

IGT Pharma presents to international meeting on brain receptor technology IGT Pharma Inc IGT Shares issued 8,819,820 Sep 29 close $0.80 Thu 30 Sept 99 News Release Mr. Bruce Schmidt reports Results of recent advances in IGT's neurological drug development programs were presented on September 22 to the third international meeting on metabotropic glutamate receptors held in Sicily. The purpose of the meeting was to bring together scientists from leading academic, biotech and pharmaceutical organizations to report on leading-edge research relating to the use of metabotropic glutamate receptor technology in the treatment of neurological disorders. The mGluRs are now widely accepted as being the basis for a new generation of neurological drugs promising to treat neurological dysfunction more effectively and specifically than currently available treatments. Dr. Ken Curry, IGT's vice-president of research and development, presented various aspects of IGT's neuroprotective drug program, including data relating to the ability of the new drug, IGT 440103, to protect rodent brain cells from damage related to oxygen deprivation, a condition related to human stroke. Initial partnering and collaboration discussions were initiated during the meeting that may lead to expanded relationships with academic institutions and pharmaceutical organizations wishing to use IGT's technology. IGT and Dr. Curry have been acknowledged as leaders in the discovery of novel amino acids that efficiently interact with the mGluR system. IGT has recently patented five broad classes of rationally synthesized amino acids that may represent new possibilities in the treatment of stroke, epilepsy, as well as psychiatric conditions such as schizophrenia and anxiety.